“We are pleased to welcome Wendy and Banmeet to the Harpoon leadership team,” said Julie Eastland, President and CEO of Harpoon Therapeutics ( HARP). He previously served in multiple leadership and scientific roles at NantKwest, Astellas (Agensys) and Genentech. Anand served as Vice President, Head of Nonclinical Development/Clinical Pharmacology at Molecular Templates. Anand brings more than 18 years of experience leading translational research and implementing drug discovery and development strategies for unmet medical needs across multiple therapeutic areas and clinical modalities. She previously served as Vice President, Human Resources at Gilead Sciences and, earlier in her career, at Bio-Rad Laboratories.ĭr. She comes to Harpoon from IDbyDNA where she served as Vice President, Head of People & Culture.
Chang has over 20 years of human resources experience in life sciences and an extensive background in aligning talent with organizations’ overall vision and direction. Anand bring deep experience to their respective roles, enhancing strategic and scientific guidance within the organization to drive the company forward in a year of anticipated clinical advancements across Harpoon’s portfolio. ( HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine. SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc.
0 kommentar(er)
